Publications

FINAL_OHE HVMF White Paper 2021_for posting 2-01

Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

1 September 2021

By placing a strain on health care systems and the global economy, the COVID-19 pandemic clearly shows the need to more comprehensively understand both supply- and…

Lower Drug

The Lower Drug Costs Now Act and Pharmaceutical Innovation

1 September 2021

The US spends significantly more on healthcare per person than other wealthy countries. H.R. 3 is a recent policy proposal aimed at reducing national spending on…

OHE Report_Henderson et al

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

1 September 2021

Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the…

OHE Consulting Report - Measuring QOL for HTA-01

How is Quality of Life Measured for Health Technology Assessments?

1 July 2021

Cost-effectiveness analysis (CEA) is the economic evaluation method that is typically preferred by health technology assessment agencies. Quality-adjusted life years (QALYs) – a composite measure of quality and…

Key considerationsfor early access schemes for single-administration (one-time)therapies-01

Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies

1 June 2021

Early access schemes enable patients in exceptional need to access therapies that are not yet available through their health system. These schemes were not designed for…

Key Factors on How to Procure, Pay and use Vaccines for COVID-19 2-01

Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective

1 May 2021

After the shock caused by the first wave of COVID-19, discovering vaccines against the virus and administering them quickly to the population became the utmost priority…

Exploring the Financial Sustainability of Gene Therapies

5 January 2021

Gene therapies represent a paradigm shift in medicine, with the potential to address the root causes of chronic diseases. They offer one-time treatment regimens and, in some cases, potentially a cure. As a result, they offer transformative value for patients, physicians, health systems and society. However, with the prospect of more gene therapy approvals there is concern in Europe that these technologies could threaten the financial sustainability of health systems.

Cracks through the ice on a melting glacier in Alaska

The Promise of Gene Therapies: Are We Ready?

1 April 2021

In a webinar held on 16 March 2021, Mary Harney, Annie Hubert and Simone Boselli joined OHE’s Adrian Towse to debate the issues surrounding the adoption of gene therapies. In this interactive report we highlight our 5 key takeaways from the debate with clips, quotes and highlights.

Capture

Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology

1 February 2021

Using medicines in combination can deliver better outcomes for patients across different tumour types and disease stages. Yet many HTA agencies do not find that the…